** Brokerage Evercore ISI says Johnson & Johnson's JNJ.N Q4 medtech revenue was generally in line with estimates "with strength in vision/hips offset by softer electrophysiology and advanced surgery"
** J&J reports medtech Q4 revenue of $8.19 bln vs analysts' estimates of $8.22 bln
** Brokerage says co's Q4 U.S. organic revenue growth of 2.1% in its electrophysiology $(EP)$ segment is "soft", says share losses to Boston Scientific BSX.N and Medtronic MDT.N from their ongoing PFA launches "will be a focus"
** A pulsed field ablation system (PFA) is a type of heart device to treat certain abnormal heart rhythm conditions
** Medical device maker Abbott ABT.N also reported Q4 organic sales growth of 8.8% in its EP segment, which Evercore says "seems to be holding slightly better" than J&J
** Brokerage adds J&J's soft growth in its spine segment bodes well for other device makers Stryker SYK.N, Zimmer Biomet ZBH.N, Enovis ENOV.N and Medtronic
** J&J fell 7.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。